Fiche publication


Date publication

novembre 2019

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EBERST Lauriane


Tous les auteurs :
Simmet V, Eberst L, Marabelle A, Cassier PA

Résumé

Numerous phase I trials testing immune checkpoint inhibitors (CPI)-based combinations are currently being conducted to improve response rates observed with single agents. However, methodology varies across studies, especially regarding the use of dose escalation.

Mots clés

combinations, dose escalation, immune checkpoint inhibitor, immunotherapy, phase I, recommended phase II dose

Référence

Ann Oncol. 2019 11 1;30(11):1751-1759